Global Industry Analysts, Inc., Oct 2011, Pages: 897
of
Drugs by Development Stage as of 2010 (includes
corresponding Graph/Chart) 56
PancreaticCancer 56
Table 17: PancreaticCancer Drug Pipeline: Number of Drugs
by Development Stage as of 2010 (includes
BioPharm Reports (VennBio Ltd.), Jan 2011, Pages: 124
and progression of the disease. These cells, named Cancer Stem Cells (CSCs), have been found in leukaemia, myeloma, breast, prostate, pancreatic, colon, brain, lung and other cancers. Findings suggest that CSCs
Global Industry Analysts, Inc., Feb 2011, Pages: 682
in Angiogenesis 136
The Rising Concern 136
Cancer 136
Cancer Statistics in US 136
A Picture of Colon Cancer in the US 136
PancreaticCancer 136
Vital Statistics 137
Table 17: New Cancer Cases in the US
Global Industry Analysts, Inc., Oct 2010, Pages: 659
Into Collaborations for PancreaticCancer Tests 71
Transgenomic Licenses Intellectual Property from Integragen 71
Health Discovery Inks Agreement with Pancreas, Biliary and
Liver Surgery Center of New York 71
Global Industry Analysts, Inc., Sep 2011, Pages: 617
48
High Incidence of PancreaticCancer Drives Demand for
Apoptosis Modulators in US Market 48
Drug Approvals, Introductions & Clinical
Datamonitor, April 2010, Pages: 243
Phase II trial shows a first-line combination of Gemzar and masitinib to confer similar efficacy to Gemzar monotherapy and other Gemzar-based combinations in pancreaticcancer
Encouraging Phase II
Elsevier Science and Technology, April 2011, Pages: 540
in PancreaticCancer
311 . Trophic Effects of Gut Hormones in the Gastrointestinal Tract
312 . The Neurotrophin Factors
313 . Cell to Cell and Cell-Matrix Interactions in Bone
314 . Cell-Cell
Datamonitor, Dec 2009, Pages: 174
SWOT analysis
Clinical trial data
One Phase III study of GV-1001 in pancreaticcancer has been terminated
Phase I/II data show that GV-1001 plus GM-CSF induces an immune response in unresectable
Global Industry Analysts, Inc., Jan 2011, Pages: 442
RASI Ink Master Services Agreement for Generx
Ceregene Commences New Phase I/II Trial for CERE-120 in
Parkinsons Disease
GeneVec Discontinues TNFerade Trial in PancreaticCancer
Transgene Grants
Elsevier Science and Technology, July 2009, Pages: 680
Translation of Stem Cells
PART TWO
BASIC BIOLOGY/MECHANISMS
6. Molecular Basis of Pluripotency
7. Stem Cell Niches
8. Mechanisms of Stem Cell Self-Renewal
9. Cell Cycle Regulators in Stem Cells
10
Global Industry Analysts, Inc., Oct 2010, Pages: 381
are provided for the period 2009 through 2015. A six-year historic analysis is also provided for these markets. The report profiles 106 companies including many key and niche players such as Bio
Global Industry Analysts, Inc., Feb 2011, Pages: 566
and niche players such as Advanced Cell Technology, Inc., Athersys, Inc., BioE, Inc., Cryo-Cell International, Inc., Cytori Therapeutics, Inc., Edstrom Biosciences, Inc., Geron Corporation, International Stem
TriMark Publications, June 2010, Pages: 266
is determined by both intrinsic regulators and the extra-cellular environment (niche), and their expansion and differentiation ex vivo are generally controlled by growing them in a specific configuration
